B. ORBITELLO, P.L. ROCCO - Vol. 9, September 2003, Issue 3
Testo Immagini Bibliografia Summary Indice
Psicofarmacoterapia dei disturbi alimentari
Psychopharmacotherapy of eating disorders
1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, 4th Edition. Am Psychiatr Ass Washington, D.C. 1994. (Trad. it. DSM-IV. Manuale diagnostico e statistico dei disturbi mentali. Milano: Masson 1996).
2 Szmukler G, Dare C, Treasure J. Handbook of eating disorders, theory, treatment and research. New York: Wiley 1995.
3 Cotrufo P, Barretta V, Monteleone P, Maj M. Full-syndrome, partial-syndrome and sub clinical eating disorders: an epidemiological study of female students in southern Italy. Acta Psychiatr Scand 1998;98:112-5.
4 Stein D, Meged S, Bar-Hanin T, Blank S, Elizur A, Weizman A. Partial Eating Disorders in Community Sample of Females Adolescents. J Am Acad Child Psychiatry 1997;36:1116-23.
5 Mizes JS, Sloan DM. An Empirical Analysis of Eating Disorder Not Otherwise Specified: Preliminary Support for a Distinct Subgroup. Intern J Eat Dis 1998;23:233-42.
6 Nicholls D, Chater R, Lask B. Children into DSM don’t go: a comparison of classification systems for eating disorders in childhood and early adolescence. Intern J Eat Dis 2000;28:317-24.
7 Santonastaso P, Zanetti T, Sala A, Favaretto G, Vidotto G, Favaro A. Prevalence of eating disorders in Italy: a survey on a sample of sixteen-years-old female students. Psychoter Psychosom 1996;65:158-62.
8 Garfinkel PE, Garner DM. Anorexia Nervosa: a multidimensional perspective. New York: Brunner & Mazel 1982.
9 Kaye WH, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry 1998;44:825-38.
10 Garfinkel PE, Walsh T. Drug therapies. In: Garner DM, Garfinkel PE, eds. Handbook of treatment for eating disorders. Second Edition. New York: Guilford Press 1997:372-80.
11 Gillberg IC, Rastam M, Gillberg C. Anorexia nervosa autcome: six-year controlled longitudinal study of 51 cases including a population cohort. J Am Acad Child Adolescent Psychiatry 1994;33:729-32.
12 Srinivasagam NM, Kaye WH, Plotnicov KH. Persistent perfectionism, symmetry and exactness after long-term recovery from anorexia nervosa. Am J Psychiatry 1995;152:1630-4.
13 American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders (revision). Am J Psychiatry 2000;157(Suppl 1):1-39.
14 Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry 1995;152:1073-4.
15 Sullivan PF, Bulik CM, Fear JL, Pickering A. Outcome of Anorexia Nervosa: A Case-Control Study. Am J Psychiatry 1998;155:939-46.
16 Steinhausen HC. The Outcome of Anorexia Nervosa in the 20th Century. Am J Psychiatry 2002;159:1284-93.
17 Ferguson CP, La Via MC, Crossan PJ, Kaye WH. Are serotonin selective reuptacke inhibitors effective in underweight anorexia nervosa? Intern J Eat Dis 1999;25:11-7.
18 Bergh C, Eriksson M, Lindberg G, Sodersten P. Selective serotonin reuptake inhibitors in anorexia. Lancet 1996;348:1459-60.
19 Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramina on a refeeding anorexia nervosa population. Postgraduate Med J 1980;56(Suppl 1):79-85.
20 Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, et al. Amitriptyline in the treatment of anorexia nervosa: a double-bind, placebo controlled study. J Clin Psychopharmacol 1985;5:10-6.
21 Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998;155:548-51.
22 Kaye WH, Nagata T, Weltzin TE, Hsu LKG, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetina in restricting and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001;49:644-52.
23 Fassino S, Leombruni P, Daga G, Brustolin A, Migliaretti G, Cavallo F, et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 2002;12:453-9.
24 Santonastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an controlled trial. J Child Adolescent Psychopharmacol 2001;11:143-50.
25 Ricca V, Mannucci E, Paionni A, Di Bernardo M, Cellini M, Cabras PL, et al. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eating Weight Disord 1999;4:10-4.
26 Vigersky RA, Loriaux DL. The effect of ciproheptadine in anorexia nervosa. In: Vigersky RA, ed. Anorexia nervosa. New York: Raven Press 1977:349-56.
27 Crisp AH. Some possible approaches to prevention of eating and body weight/shape disorders with particular reference to anorexia nervosa. Intern J Eating Disord 1988;7:1-17.
28 Lennkh C, DeZwaan M, Kasper S. New aspects of diagnosis and pharmacotherapy of eating disorders. Intern J Psychiatry Clin Practice 1997;1:21-3.
29 Cassano GB, Miniati M, Pini S, Rotondo A, Banti S, Borri C, et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Intern J Eating Disord 2003;33:172-7.
30 Hansen L. Olanzapine in the treatment of anorexia nervosa (letter). Br J Psychiatry 1999;175:592-ultima pagina.
31 Jensen VS, Mejlhede A. Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 2000;177:87-ultima pagina.
32 Powers PS, Santana CA, Bannon VS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Intern J Eating Disord 2002;32:146-54.
33 Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, et al. Olanzapine treatment of anorexia nervosa: A retrospective study. Intern J Eating Disord 2003; 33:234-7.
34 Moore R, Mills H. Naloxone in the treatment of anorexia nervosa. Effect on weight gain and lipolysis. J R Soc Med 1981;74:129-31.
35 Gross HA, Ebert MH, Faden VB. A double-blind controlled trial of lithium carbonate in primary anorexia nervosa. J Clin Pharmacol 1981;8:376-81.
36 Su JC, Birmingham CL. Zinc supplementation in the treatment of anorexia nervosa. Eating Weight Disord 2002;7:20-2.
37 Keel PK, Mitchell JE, Miller KB, Davis TL, Crow SJ. Long-term outcome of bulimia nervosa. Arch Gen Psychiatry 1998;56:63-9.
38 Fichter MM, Quadflieg N. Six-year course of bulimia nervosa. Intern J Eating Disord 1997;22:361-84.
39 Nakash-Eisikovitz O, Dierberg A, Western D. A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarizing the range of outcome in controlled clinical trials. Harvard Rev Psychiatry 2002;10:193-211.
40 Wilson GT, Fairburn CG, Agras WS. Cognitive-behavioral therapy for bulimia nervosa. In: Garner DM, Garfinkel PE, eds. Handbook of Treatment for Eating Disorders. New York, NY: Guilford Press 1997:67-93.
41 Fairburn CG, Norman PA, Welch SL. A prospective study of outcome in bulimia nervosa and the long term effects of three psychological treatment. Arch Gen Psychiatry 1995;52:304-12.
42 Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, Roose SP, et al. Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry 1997;154:523-31.
43 Agras WS, Walsh T, Fairburn CG, Wilson GT, Kraemer HC. A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa. Arch Gen Psychiatry 2000;57:459-66.
44 Mayer LES, Walsh BT. The use of selective serotonin reuptake inhibitors in eating disorders. J Clin Psychiatry 1998;59(Suppl 15):28-34.
45 Agras WS, Dorian B, Kirkley BG. Imipramine in the treatment of bulimia nervosa: a double-bind controlled study. Intern J Eating Disord 1987;6:29-38.
46 Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM. Treating bulimia with desipramine: A double-blind, placebo controlled study. Arch Gen Psychiatry 1986;43:182-6.
47 Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter placebo-controlled double-blind trial. Arch Gen Psychiatry 1992;49:139-47.
48 Goldstein DJ, Wilson MG, Thompson VL. Long term fluoxetine treatment of bulimia nervosa. Br J Psychiatry 1995;166:660-6.
49 Goldstein DJ, Wilson MG, Ascroft RC, al-Banna M. Effectiveness of fluoxetina therapy in bulimia nervosa regardless of comorbid depression. Intern J Eating Disord 1999;25:19-27.
50 Mitchell JE, Fletcher L, Hanson K, Mussell MP, Seim H, Crosby R, et al. The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. J Clin Pharmacol 2001;21:298-304.
51 Horne RL, Ferguson JM, Pope HG. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988;49:262-6.
52 Ayuso-Guttierrez JM, Palazon M, Ayuso-Mateos JL. Open trial of fluvoxamine in the treatment of bulimia nervosa. Intern J Eating Disord 1994;15:245-9.
53 Mizes JS, Denise MS, Stephen R. The efficacy of sertraline in bulimia nervosa patients. Pittsburgh, PA: Proceed Eating Disord Res Soc Meeting 1996 Nov 13-16.
54 Pigott TA, Sunderland BA, Horn L. A pilot study of paroxetine in the treatment of patients with bulimia nervosa. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association; May 7, 1996; New York, NY. Abstract NR416: 181.
55 Geretsegger C, Greimel KV, Roed IS. Ipsapirone in the treatment of bulimia nervosa: an open pilot study. Intern J Eating Disord 1995;17:359-63.
56 Kim SW, Hartmann BK, Faris PL. Bulimia nervosa: effects of ondansetron on binge/vomiting sequences. Proceedings of the 7th New York International Conference on Eating Disorders; 1996 Apr 25-28, New York.
57 Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000;355:792-7.
58 Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry 1988;45:471-5.
59 Kennedy SH, Goldbloom DS, Raleveski E. Is there a role of selective monoamino oxydase inhibitor therapy in bulimia nervosa? A placebo controlled trial with brofaromine. Intern J Psychopharmacol 1993;3:415-22.
60 Pope Hg, Keck PE, McElroy SM, Hudson JI. A placebo controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989;9:254-9.
61 Ficher MM, Kruger R, Rief W, Holland R, Dohne J. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 1996;16:9-18.
62 El-Giamal N, de Zwaan M, Bailer U, Lennkh C, Schussler P, Strnad A, et al. Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Intern Clin Psychopharmacol 2000;15:351-6.
63 Walsh BT, Gladis M, Roose SP, Stewart JW, Glassman AH. A controlled trial of phenelzine in bulimia. Psychopharmacol Bull 1987;23:49-51.
64 Carruba MO, Cuzzolaro M, Riva L, Bosello O, Liberti S, Castra R, et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Intern Clin Psychopharmacol 2001;16:27-32.
65 Bacaltchuk J, Hay P. Antidepressant versus placebo for people with bulimia nervosa. Cochrane Database System Review 2001;4:CD003391.
66 Calandra C, Gulino V, Inserra L, Giuffrida A. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eating Weight Disord 1999;4:207-10.
67 Marrazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int J Psychopharmacol 1995;10:163-70.
68 Bandecchi A. Fluoxetine plus naltrexone in the treatment of bulimia nervosa. European Neuropsychopharmacology: J Europ Coll Neuropsychopharmacol 1996;6(Suppl 3):70-3.
69 De Zwaan M, Mitchell JE. Opiate antagonosts and eating behavior. J Clin Pharmacol 1992;32:1060-72.
70 Spitzer RL, Devlin MJ, Walsh BT. Binge eating disorder: a multisite field trial for the diagnostic criteria. Intern J Eating Disord 1992;11:191-203.
71 Spitzer RL, Yanovski S, Wadden T, Wing R, Marcus MD, Stunkard A, et al. Binge eating disorder: its further validation in a multisite study. Intern J Eating Disord 1993;13:137-53.
72 Fairburn CG, Cooper Z, Doll HA, Norman P, O’Connor M. The natural course of bulimia nervosa and binge eating disorder in young women. Arch Gen Psychiatry 2000;57:659-65.
73 Goldfein JA, Walsh BT, LaChaussee JL, Kissileff HR, Devlin MJ. Eating behavior in binge eating disorder. Intern J Eating Disord 1993;14:427-31.
74 Herzog DB, Hopkins JD, Burns CD. A follow-up study of 33 subdiagnostic eating disordered women. Intern J Eating Disord 1993;14:261-7.
75 Wilson GT, Fairburn CC, Agras WS, Walsh BT, Kraemer H. Cognitive-behavioral therapy for bulimia nervosa: time course and mechanisms of change. J Cons Clin Psychol 2002;70:267-74.
76 Devlin MJ. Treatment of binge eating disorder with psychotherapy and medication. Proceedings of the 7th International Conference on Eating Disorders: 1996, April 26-28, New York, NY.
77 Arnold LM, McElroy SL, Hudson JL, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomized trial of fluoxetina in the treatment of binge-eating disorder. J Clin Psychiatry 2002;63:1028-33.
78 Ricca V, Mannucci E, Mezzani B, Moretti S, Di Bernardo M, Bertelli M, et al. Fluoxetina and fluvoxamina combined with individual cognitive behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001;70:298-306.
79 Hudson JL, McElroy SL, Raymond NC, Crow S, Keck PE, Carter WP, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-bind trial. Am J Psychiatry 1998;155:1756-62.
80 Hudson JL, McElroy SL, Raymond NC. Fluvoxamine treatment of binge-eating disorder: a multicenter, placebo-controlled trial. In: New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association; May 26, 1994; Philadelphia, Pa. Abstract NR620: 218
81 McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA, Keck PE, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000;157:1004-6.
82 Malhotra S, King KH, Welge JA, Brusman-Lovins L, McElroy SL. Venlafaxine treatment of binge eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry 2002;63:802-6.
83 McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 200;160:255-61.
84 Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge eating disorder with Topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-72
85 Pruzinsky T, Cash TF. Integrative themes in body images development, deviance, and change. In: Cash TF, Pruzinsky T. Body images. New-York: Guilford Press 1990.
86 Biasin E, Rocco PL. Distorsioni dell’immagine corporea nei disturbi del comportamento alimentare: una rassegna. Psichiatria Generale dell’Età Evolutiva 37, 2000.
87 Hsu LK, Sobkiewicz TA. Body image disturbance: time to abandone the concept for eating disorder? Intern J Eating Disord 1991;10:15-30.
88 Palmer RL. Weight concern should not be a necessary criterion for the eating disorders: a polemic. Intern J Eating Disord 1993;14:459-65.
89 Horne RL, Van-Vactor JC, Emerson S. Disturbed body image in patients with eating disorders. Am J Psychiatry 1991;148:211-5.
90 Rabe-Jablonska JJ, Sobow TM. The links between body dysmorphic disorder and eating disorders. Europ Psychiatry 2000;15:302-5.
91 Rabe-Jablonska JJ. Liaison between body dysmorphic disorder and eating disorders. Psychiatria Polska 1998;32:155-63.
92 Grant JE, Kim SW, Eckert ED. Body dysmorphic disorder in patients with anorexia nervosa: prevalence, clinical features, and delusionality of body image. Intern J Eating Disord 2002;32:291-300.
93 Rosen JC, Ramirez E. A comparison of eating disorders and body dysmorphic disorder on body image and psychological adjustment. J Psychosom Res 1998;44:441-9.
94 Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamina in the treatment of body dysmorphic disorder (dysmorphophobia). Intern Clin Psychopharmacol 1996;11:247-54.
95 Phillips KA. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin 1998;62:A33-A48.
96 Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine vs. Desipramine Crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999;56:1033-42.
97 Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetina in body dysmorphic disorder. Arch Gen Psychiatry 2002;59:381-8.
98 Hadley SJ, Greenberg J, Hollander E. Diagnosis and treatment of body dysmorphic disorder in adolescents. Current Psychiatry Report 2002;4:108-13.
99 Rosen JC. Body image assessment and treatment in controlled studies of eating disorders. Intern J Eating Disord 1996;20:331-43.